Aline Andrea da Cunha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aline Andrea da Cunha has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Géssica Luana Antunes
A Laboratory of Pediatric Respirology, Infant Center, Institute of Biomedical Research , Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre , Brazil
3 shared publicationsJosiane Silva Silveira
A Laboratory of Pediatric Respirology, Infant Center, Institute of Biomedical Research , Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre , Brazil
3 shared publicationsMauro Henrique Moraes Vargas
A Laboratory of Pediatric Respirology, Infant Center, Institute of Biomedical Research , Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre , Brazil
3 shared publicationsNailê Karine Nuñez
A Laboratory of Pediatric Respirology, Infant Center, Institute of Biomedical Research , Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre , Brazil
3 shared publicationsPaulo Márcio Pitrez
A Laboratory of Pediatric Respirology, Infant Center, Institute of Biomedical Research , Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre , Brazil
3 shared publicationsRodrigo Godinho de Souza
A Laboratory of Pediatric Respirology, Infant Center, Institute of Biomedical Research , Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre , Brazil
3 shared publications
Latest Publications
- 1 January 2017
- Published by Tikinet Edicao Ltda. - EPP in Clinical and Biomedical Research
- Vol. 37 (2) , 132-139
REVISÃO SISTEMÁTICA SOBRE MODELOS EXPERIMENTAIS DE ASMA AGUDA E CRÔNICA INDUZIDOS COM EXTRATO DE ÁCARO DA POEIRA DOMÉSTICA
- 1 January 2017
- Published by Tikinet Edicao Ltda. - EPP in Clinical and Biomedical Research
- Vol. 37 (2) , 132-139
REVISÃO SISTEMÁTICA SOBRE MODELOS EXPERIMENTAIS DE ASMA AGUDA E CRÔNICA INDUZIDOS COM EXTRATO DE ÁCARO DA POEIRA DOMÉSTICA
- 1 November 2016
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 44 (6) , 504-511
Bacterial extract (OM-85) with human-equivalent doses does not inhibit the development of asthma in a murine model
OM-85 is an immunostimulant bacterial lysate, which has been proven effective in reducing the number of lower airways infections. We investigated the efficacy of the bacterial lysate OM-85 in the primary prevention of a murine model of asthma. In the first phase of our study the animals received doses of 0.5μg, 5μg and 50μg of OM-85 through gavage for five days (days -10 to -6 of the protocol), 10 days prior to starting the sensitisation with ovalbumin (OVA), in order to evaluate the results of dose-response protocols. A single dose (5μg) was then chosen in order to verify in detail the effect of OM-85 on the pulmonary allergic response. Total/differential cells count and cytokine levels (IL-4, IL-5, IL-13 and IFN-γ) from bronchoalveolar lavage fluid (BALF), OVA-specific IgE levels from serum, lung function and lung histopathological analysis were evaluated. OM-85 did not reduce pulmonary eosinophilic response, regardless of the dose used. In the phase protocol using 5μg/animal of OM-85, no difference was shown among the groups studied, including total cell and eosinophil counts in BALF, serum OVA-specific IgE, lung histopathologic findings and lung resistance. However, OM-85 decreased IL-5 and IL-13 levels in BALF. OM-85, administered in early life in mice in human-equivalent doses, does not inhibit the development of allergic pulmonary response in mice.
- 1 November 2016
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 44 (6) , 504-511
Bacterial extract (OM-85) with human-equivalent doses does not inhibit the development of asthma in a murine model
OM-85 is an immunostimulant bacterial lysate, which has been proven effective in reducing the number of lower airways infections. We investigated the efficacy of the bacterial lysate OM-85 in the primary prevention of a murine model of asthma. In the first phase of our study the animals received doses of 0.5μg, 5μg and 50μg of OM-85 through gavage for five days (days -10 to -6 of the protocol), 10 days prior to starting the sensitisation with ovalbumin (OVA), in order to evaluate the results of dose-response protocols. A single dose (5μg) was then chosen in order to verify in detail the effect of OM-85 on the pulmonary allergic response. Total/differential cells count and cytokine levels (IL-4, IL-5, IL-13 and IFN-γ) from bronchoalveolar lavage fluid (BALF), OVA-specific IgE levels from serum, lung function and lung histopathological analysis were evaluated. OM-85 did not reduce pulmonary eosinophilic response, regardless of the dose used. In the phase protocol using 5μg/animal of OM-85, no difference was shown among the groups studied, including total cell and eosinophil counts in BALF, serum OVA-specific IgE, lung histopathologic findings and lung resistance. However, OM-85 decreased IL-5 and IL-13 levels in BALF. OM-85, administered in early life in mice in human-equivalent doses, does not inhibit the development of allergic pulmonary response in mice.
- 7 February 2016
- Published by Taylor & Francis in Experimental Lung Research
- Vol. 42 (2) , 66-74
Recombinant human deoxyribonuclease therapy improves airway resistance and reduces DNA extracellular traps in a murine acute asthma model
Purpose: Asthma is a highly prevalent chronic inflammatory lung disease characterized by airway hyperresponsiveness to allergens, airway edema, and increased mucus secretion. Such mucus can be liquefied by recombinant human deoxyribonuclease (rhDNase), in which efficacy of rhDNase has been well documented in patients with cystic fibrosis, but little studied in asthma. In the present study, we investigated whether rhDNase intranasal administration improved inflammation and pulmonary function in an experimental model of asthma. Methods: Mice were sensitized by two subcutaneous injections of ovalbumin (OVA), on days 0 and 7, followed by three intranasal challenges with OVA on days 14, 15, and 16. A control group, replacing OVA by DPBS, was included. On days 15 and 16, after 2 hours of OVA challenge, mice received 1 mg/mL of intranasal rhDNase. Results: We showed that rhDNase decreased significantly the airway resistance and reduced EETs formation and globet cells hyperplasia. Conclusions: Our results suggest that extracellular DNA in mucus play a role in lower airways obstruction in OVA asthma protocol and that the treatment with rhDNase improved lung function and DNA extracellular traps, with no direct cellular anti-inflammatory effects.
- 7 February 2016
- Published by Taylor & Francis in Experimental Lung Research
- Vol. 42 (2) , 66-74
Recombinant human deoxyribonuclease therapy improves airway resistance and reduces DNA extracellular traps in a murine acute asthma model
Purpose: Asthma is a highly prevalent chronic inflammatory lung disease characterized by airway hyperresponsiveness to allergens, airway edema, and increased mucus secretion. Such mucus can be liquefied by recombinant human deoxyribonuclease (rhDNase), in which efficacy of rhDNase has been well documented in patients with cystic fibrosis, but little studied in asthma. In the present study, we investigated whether rhDNase intranasal administration improved inflammation and pulmonary function in an experimental model of asthma. Methods: Mice were sensitized by two subcutaneous injections of ovalbumin (OVA), on days 0 and 7, followed by three intranasal challenges with OVA on days 14, 15, and 16. A control group, replacing OVA by DPBS, was included. On days 15 and 16, after 2 hours of OVA challenge, mice received 1 mg/mL of intranasal rhDNase. Results: We showed that rhDNase decreased significantly the airway resistance and reduced EETs formation and globet cells hyperplasia. Conclusions: Our results suggest that extracellular DNA in mucus play a role in lower airways obstruction in OVA asthma protocol and that the treatment with rhDNase improved lung function and DNA extracellular traps, with no direct cellular anti-inflammatory effects.
- 6 January 2016
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 413 (1-2) , 47-55
Recombinant human deoxyribonuclease attenuates oxidative stress in a model of eosinophilic pulmonary response in mice
The inflammatory cells infiltrating the airways produce several mediators, such as reactive oxygen species (ROS). ROS and the oxidant-antioxidant imbalance might play an important role in the modulation of airways inflammation. In order to avoid the undesirable effects of ROS, various endogenous antioxidant strategies have evolved, incorporating both enzymatic and non-enzymatic mechanisms. Recombinant human deoxyribonuclease (rhDNase) in clinical studies demonstrated a reduction in sputum viscosity, cleaving extracellular DNA in the airways, and facilitating mucus clearance, but an antioxidant effect was not studied so far. Therefore, we evaluated whether the administration of rhDNase improves oxidative stress in a murine model of asthma. Mice were sensitized by two subcutaneous injections of ovalbumin (OVA), on days 0 and 7, followed by three lung challenges with OVA on days 14, 15, and 16. On days 15 and 16, after 2 h of the challenge with OVA, mice received 1 mg/mL of rhDNase in the lungs. Bronchoalveolar lavage fluid and lung tissue were obtained on day 17, for inflammatory and oxidative stress analysis. We showed that rhDNase did not alter the population of inflammatory cells, such as eosinophil cells, in OVA-treated rhDNase group but significantly improved oxidative stress in lung tissue, by decreasing oxygen reactive species and increasing superoxide dismutase/catalase ratio, glutathione peroxidase activity, and thiol content. Our data provide the first evidence that rhDNase decreases some measures of oxidative stress and antioxidant status in a murine model of asthma, with a potential antioxidant effect to be further studied in human asthma.
- 6 January 2016
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 413 (1-2) , 47-55
Recombinant human deoxyribonuclease attenuates oxidative stress in a model of eosinophilic pulmonary response in mice
The inflammatory cells infiltrating the airways produce several mediators, such as reactive oxygen species (ROS). ROS and the oxidant-antioxidant imbalance might play an important role in the modulation of airways inflammation. In order to avoid the undesirable effects of ROS, various endogenous antioxidant strategies have evolved, incorporating both enzymatic and non-enzymatic mechanisms. Recombinant human deoxyribonuclease (rhDNase) in clinical studies demonstrated a reduction in sputum viscosity, cleaving extracellular DNA in the airways, and facilitating mucus clearance, but an antioxidant effect was not studied so far. Therefore, we evaluated whether the administration of rhDNase improves oxidative stress in a murine model of asthma. Mice were sensitized by two subcutaneous injections of ovalbumin (OVA), on days 0 and 7, followed by three lung challenges with OVA on days 14, 15, and 16. On days 15 and 16, after 2 h of the challenge with OVA, mice received 1 mg/mL of rhDNase in the lungs. Bronchoalveolar lavage fluid and lung tissue were obtained on day 17, for inflammatory and oxidative stress analysis. We showed that rhDNase did not alter the population of inflammatory cells, such as eosinophil cells, in OVA-treated rhDNase group but significantly improved oxidative stress in lung tissue, by decreasing oxygen reactive species and increasing superoxide dismutase/catalase ratio, glutathione peroxidase activity, and thiol content. Our data provide the first evidence that rhDNase decreases some measures of oxidative stress and antioxidant status in a murine model of asthma, with a potential antioxidant effect to be further studied in human asthma.
- Open Access
- 1 January 2016
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 6 (1) , 48-55
Acute and chronic exposure to Tyrophagus putrescentiae induces allergic pulmonary response in a murine model
Nuñez NK, et al. Asia Pac Allergy. 2016 Jan;6(1):48-55. https://doi.org/10.5415/apallergy.2016.6.1.48
- 1 January 2016
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 6 (1) , 48-55
Open AccessAcute and chronic exposure to Tyrophagus putrescentiae induces allergic pulmonary response in a murine model
Nuñez NK, et al. Asia Pac Allergy. 2016 Jan;6(1):48-55. https://doi.org/10.5415/apallergy.2016.6.1.48
Extracellular DNA traps in bronchoalveolar fluid from a murine eosinophilic pulmonary response
Asthma is associated with a loss of the structural integrity of airway epithelium and dysfunction of the physical barrier, which protects airways from external harmful factors. Granulocyte activation causes the formation of extracellular traps, releasing web-like structures of DNA and proteins, being important to kill pathogens extracellularly. We investigated whether eosinophils infiltrating airways in an experimental model of asthma would induce eosinophil extracellular traps (EETs) in bronchoalveolar lavage fluid and lung tissue. We showed that an ovalbumin (OVA) asthma protocol presented a significant increase in eosinophil counts with increased extracellular DNA in bronchoalveolar lavage fluid as well as in lung tissue, confirming the presence of DNA traps colocalized with eosinophil peroxidase. EETs formation was reversed by DNase treatment. With these approaches, we demonstrated for the first time that OVA-challenged mice release extracellular DNA traps, which could aggravate pulmonary dysfunction.
Extracellular DNA traps in bronchoalveolar fluid from a murine eosinophilic pulmonary response
Asthma is associated with a loss of the structural integrity of airway epithelium and dysfunction of the physical barrier, which protects airways from external harmful factors. Granulocyte activation causes the formation of extracellular traps, releasing web-like structures of DNA and proteins, being important to kill pathogens extracellularly. We investigated whether eosinophils infiltrating airways in an experimental model of asthma would induce eosinophil extracellular traps (EETs) in bronchoalveolar lavage fluid and lung tissue. We showed that an ovalbumin (OVA) asthma protocol presented a significant increase in eosinophil counts with increased extracellular DNA in bronchoalveolar lavage fluid as well as in lung tissue, confirming the presence of DNA traps colocalized with eosinophil peroxidase. EETs formation was reversed by DNase treatment. With these approaches, we demonstrated for the first time that OVA-challenged mice release extracellular DNA traps, which could aggravate pulmonary dysfunction.